{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:22:28Z","timestamp":1788013348374,"version":"build-2784847793"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-34147-4","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T04:25:48Z","timestamp":1769401548000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world analysis of multiple myeloma treatments in England using the Cancer Analysis System registry"],"prefix":"10.1038","volume":"16","author":[{"given":"Elma Mary","family":"Babu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheetal","family":"Fermahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kellyn","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Broe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lay-Flurrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panteleimon","family":"Matsakidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mersha","family":"Chetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Pawlyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"34147_CR1","unstructured":"NICE, Multiple Myeloma & Summary https:\/\/cks.nice.org.uk\/topics\/multiple-myeloma\/ (2022)."},{"key":"34147_CR2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan, A. J. et al. Diagnosis and management of multiple myeloma: a review. JAMA 327, 464\u2013477 (2022).","journal-title":"JAMA"},{"key":"34147_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk, N., Pawlyn, C. & Yong, K. L. Multiple myeloma. Lancet 397, 410\u2013427 (2021).","journal-title":"Lancet"},{"key":"34147_CR4","first-page":"220","volume":"1","author":"AG Szabo","year":"2019","unstructured":"Szabo, A. G. et al. The clinical course of multiple myeloma in the era of novel agents: a retrospective, single-center, real-world study. Clin. Hematol. Int. 1, 220\u2013228 (2019).","journal-title":"Clin. Hematol. Int."},{"key":"34147_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41408-021-00432-4","volume":"11","author":"E Terpos","year":"2021","unstructured":"Terpos, E. et al. Management of patients with multiple myeloma beyond the clinical-trial setting: Understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer J. 11, 40 (2021).","journal-title":"Blood Cancer J."},{"key":"34147_CR6","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos, M. A. et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 32, 309\u2013322 (2021).","journal-title":"Ann. Oncol."},{"key":"34147_CR7","unstructured":"NICE & Myeloma Diagnosis and management NICE guideline NG35. https:\/\/www.nice.org.uk\/guidance\/ng35 (2023)."},{"key":"34147_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/bjh.14193","volume":"175","author":"MS Raab","year":"2016","unstructured":"Raab, M. S. et al. Multiple myeloma: practice patterns across Europe. Br. J. Haematol. 175, 66\u201376 (2016).","journal-title":"Br. J. Haematol."},{"key":"34147_CR9","unstructured":"ESMO & EnLiST- ESMO-Adaptation-of-Line-of-Systemic-Therapy-Appendix. https:\/\/www.esmo.org\/content\/download\/733928\/17309663\/1\/EnLiST-ESMO-Adaptation-of-Line-of-Systemic-Therapy-Appendix.pdf (2022)."},{"key":"34147_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/ije\/dyz137","volume":"49","author":"CJ Bright","year":"2020","unstructured":"Bright, C. J. et al. Data resource profile: the systemic anti-cancer therapy (SACT) dataset. Int. J. Epidemiol. 49, 15\u201315l (2020).","journal-title":"Int. J. Epidemiol."},{"key":"34147_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ije\/dyz076","volume":"49","author":"KE Henson","year":"2020","unstructured":"Henson, K. E. et al. Data resource profile: National Cancer Registration Dataset in England. Int. J. Epidemiol. 49, 16\u201316\u00a0h (2020).","journal-title":"Int. J. Epidemiol."},{"key":"34147_CR12","unstructured":"NICE. Technology Appraisals Programme Specification for Cancer Drugs Fund data collection arrangements. NHS Engl. https:\/\/www.nice.org.uk\/Media\/Default\/About\/what-we-do\/NICE-guidance\/NICE-technology-appraisal-guidance\/cancer-drugs-fund\/data-collection-specification.pdf (2020)."},{"key":"34147_CR13","unstructured":"NICE. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658]. https:\/\/www.nice.org.uk\/guidance\/gid-ta10979\/documents\/scope-consultation-comments-and-responses (2024)."},{"key":"34147_CR14","unstructured":"NICE. TA311 bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation. https:\/\/www.nice.org.uk\/Guidance\/TA311 (2014)."},{"key":"34147_CR15","unstructured":"NICE. TA680 Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma. https:\/\/www.nice.org.uk\/guidance\/TA680 (2021)."},{"key":"34147_CR16","unstructured":"NICE. TA228 bortezomib and thalidomide for the first-line treatment of multiple myeloma. https:\/\/www.nice.org.uk\/Guidance\/TA228 (2011)."},{"key":"34147_CR17","unstructured":"NICE. Lenalidomide plus dexamethasone for previously untreated multiple myeloma. https:\/\/www.nice.org.uk\/guidance\/TA587 (2019)."},{"key":"34147_CR18","unstructured":"NICE. TA763 Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable. Overview | Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable | Guidance | NICE. (2022)."},{"key":"34147_CR19","unstructured":"NICE. Daratumumab with Lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable. https:\/\/www.nice.org.uk\/guidance\/TA917\/chapter\/1-Recommendations (2023)."},{"key":"34147_CR20","unstructured":"NICE. NICE real-world evidence framework. https:\/\/www.nice.org.uk\/corporate\/ecd9\/chapter\/overview (2022)."},{"key":"34147_CR21","unstructured":"Public Health England. Systemic Anti-Cancer Therapy (SACT) data set. https:\/\/digital.nhs.uk\/ndrs\/data\/data-sets\/sact (2024)."},{"key":"34147_CR22","unstructured":"NHS England. Appraisal and funding of cancer drugs from July 2016 (including the new cancer drugs Fund) A new deal for patients, taxpayers and industry. https:\/\/www.england.nhs.uk\/publication\/appraisal-and-funding-of-cancer-drugs-from-july-2016\/ (2016)."},{"key":"34147_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.7861\/clinmedicine.16-1-62","volume":"16","author":"LL Griffin","year":"2016","unstructured":"Griffin, L. L., Ali, F. R. & Lear, J. T. Non-melanoma skin cancer. Clin. Med. (Lond). 16, 62\u201365 (2016).","journal-title":"Clin. Med. (Lond)"},{"key":"34147_CR24","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jval.2023.09.2877","volume":"26","author":"C Pawlyn","year":"2023","unstructured":"Pawlyn, C. et al. Time to treatment initiation and patient characteristics in newly diagnosed multiple myeloma patients with and without transplant: real world evidence using \u2018big data\u2019 from England. Value Health. 26, 535 (2023).","journal-title":"Value Health"},{"key":"34147_CR25","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.2217\/fon-2023-0021","volume":"19","author":"J Martinez-Lopez","year":"2023","unstructured":"Martinez-Lopez, J. et al. Real-world treatment patterns, healthcare resource use and disease burden in patients with multiple myeloma in Europe. Future Oncol. 19, 2103\u20132121 (2023).","journal-title":"Future Oncol."},{"key":"34147_CR26","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/ejh.14161","volume":"112","author":"M Lehne","year":"2024","unstructured":"Lehne, M. et al. Real-world treatment patterns in patients initiating third-line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain. Eur. J. Haematol. 112, 701\u2013713 (2024).","journal-title":"Eur. J. Haematol."},{"key":"34147_CR27","first-page":"5","volume":"4","author":"S Kurtin","year":"2013","unstructured":"Kurtin, S. Relapsed or relapsed\/refractory multiple myeloma. J. Adv. Pract. Oncol. 4, 5\u201314 (2013).","journal-title":"J. Adv. Pract. Oncol."},{"key":"34147_CR28","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bjh.14213","volume":"175","author":"K Yong","year":"2016","unstructured":"Yong, K. et al. Multiple myeloma: patient outcomes in real-world practice. Br. J. Haematol. 175, 252\u2013264 (2016).","journal-title":"Br. J. Haematol."},{"key":"34147_CR29","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson, P. G. et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl. J. Med. 387, 132\u2013147 (2022).","journal-title":"N Engl. J. Med."},{"key":"34147_CR30","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1182\/bloodadvances.2019000524","volume":"4","author":"KK Nishimura","year":"2020","unstructured":"Nishimura, K. K. et al. Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood Adv. 4, 422\u2013431 (2020).","journal-title":"Blood Adv."},{"key":"34147_CR31","unstructured":"NHS Digital. Radiotherapy Data Set (RTDS). https:\/\/digital.nhs.uk\/ndrs\/data\/data-sets\/rtds (2024)."},{"key":"34147_CR32","unstructured":"NHS England. Systemic Anti-Cancer Therapy (SACT) data set review: latest update. https:\/\/digital.nhs.uk\/ndrs\/data\/data-sets\/sact#sact-data-set-review-latest-update (2024)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34147-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34147-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34147-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T10:04:37Z","timestamp":1769681077000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34147-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["34147"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-34147-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"assertion":[{"value":"19 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval from an ethics committee was not needed since this study did not involve individually identifiable patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was supported by Sanofi UK and carried out by IQVIA. Elma Mary Babu, Mersha Chetty, Sheetal Fermahan, and Jonathan Bowen are employees of Sanofi UK. Charlotte Pawlyn reports receiving honoraria from AbbVie, BMS\/Celgene, GSK, Janssen, Pfizer, Sanofi, and iTEOS therapeutics, as well as research funding from Janssen.Kellyn Arnold, Anne Broe, Sarah Lay-Flurrie, and Panteleimon Matsakidis are employees of IQVIA. IQVIA received funding from Sanofi for the running of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4055"}}